Biotech Stock To Buy

 Biotech Stock To Buy

Gilead Sciences: Don't Ignore This Biotech Stock

AI stocks continue to attract investors' attention. If the AI infrastructure spending continues and these companies earn a positive ROI, it could lead to life-changing returns.

But all of this doesn't mean there are no good opportunities elsewhere. In fact, there are plenty of opportunities in the biotech sector. One particular biotech stock that you should not ignore is Gilead Sciences (GILD).

Gilead Sciences Continues To Raise Its Dividend Yield

Gilead Sciences stock has a dividend yield of 1.96%. The company has also raised its dividend yield for 10 years, which goes to show it can be good for income-seekers.

On a YTD basis, the Gilead Sciences stock price has gone up by 39%. Meanwhile, the S&P 500 index has only gained an upside of 11%. This means the biotech stock has outperformed the market index by a long mile.

In Q3 2026, the revenue of Gilead Sciences was $8.3 billion, with a 7% y/y increase. That's quite good given that the company is facing declining sales of its COVID vaccines and medicines.

For now, the company is mainly focusing on its treatment related to HIV. The sales of HIV treatment products were recorded at $6.2 billion with an 18% y/y increase. Meanwhile, the treatments and drugs for liver disease also did well. The revenue from these went up by 13% y/y and reached $927 million.

Looking ahead, Gilead Sciences is in a very good position. It has already received several approvals from the relevant regulatory bodies. One particular approval is for Bixluzent. It is an oral drug which allows patients to take a single dose instead of multiple ones.

Gilead Sciences has also gotten approval for Hepcludex, which is used for the treatment of liver disease. So, that's also something which is sure to improve revenue in the long run.

One of the most important medicines from Gilead Sciences is Biktarvy. No generic form will be available for this drug until 2036. This means the company can continue to get dependable revenue for several years.

When we consider its existing portfolio and all the exciting treatments it has in the pipeline, it becomes clear why you shouldn't ignore Gilead Sciences stock.

Trending Stories